



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/590080/2014 **Corr**

European Medicines Agency decision

P/0284/2014

of 28 October 2014

on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alfa pegol (EMEA-001174-PIP02-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0284/2014

of 28 October 2014

on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alfa pegol (EMA-001174-PIP02-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0227/2012 issued on 3 October 2012,

Having regard to the application submitted by Novo Nordisk A/S on 23 June 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 September 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for turoctocog alfa pegol, powder and solvent for solution for injection, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novo Nordisk A/S, Novo Allé, 2880 – Bagsvaerd, Denmark.

Done at London, 28 October 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/405590/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001174-PIP02-12-M01

Scope of the application

Active substance(s):

Turoctocog alfa pegol

Condition(s):

Treatment of Hereditary factor VIII deficiency

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

Novo Nordisk A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted to the European Medicines Agency on 23 June 2014 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0227/2012 issued on 3 October 2012.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 July 2014.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 12 September 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of Hereditary factor VIII deficiency

2.1.1. Indication(s) targeted by the PIP

Treatment and prophylaxis of bleeding in patients with haemophilia A (hereditary factor VIII deficiency)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Number of studies	Description
Quality	1	Study 1: Development of a 250 IU vial size
Non-clinical	0	Not applicable.
Clinical	4	Study 2: Open-label trial to evaluate pharmacokinetics, safety, efficacy of Glycopegylated recombinant coagulation factor VIII (N8-GP) in previously treated children from 12 to less than 18 years of age (and adults) with severe hereditary Factor VIII deficiency Study 3: Open-label, non-randomised trial to evaluate safety and the haemostatic effect of N8-GP during surgical procedures in children with haemophilia A from 12 years to less than 18 years of age (and adults) Study 4: Open-label trial to evaluate pharmacokinetics, safety, efficacy of N8-GP in previously treated children less than 12 years of age with Haemophilia A

		Study 5: Open-label trial to evaluate safety, efficacy, immunogenicity of N8-GP in previously untreated children from birth to less than 6 years of age with hereditary Factor VIII deficiency.
--	--	---

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes